Ken Griffin Amneal Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$5.36 - $7.11 $54,672 - $72,522	10,200 Added 3400.0%	10,500 $66,000
Q1 2024 May 15, 2024	SELL	$5.24 - $6.34 $33,012 - $39,942	-6,300 Reduced 95.45%	300 $1,000
Q4 2023 Feb 14, 2024	SELL	$3.36 - $6.21 $5,712 - $10,557	-1,700 Reduced 20.48%	6,600 $40,000
Q3 2023 Nov 14, 2023	BUY	$2.76 - $4.59 $6,623 - $11,016	2,400 Added 40.68%	8,300 $35,000
Q2 2023 Aug 14, 2023	SELL	$1.33 - $3.1 $19,551 - $45,570	-14,700 Reduced 71.36%	5,900 $18,000
Q1 2023 May 15, 2023	SELL	$1.27 - $2.7 $1,397 - $2,970	-1,100 Reduced 5.07%	20,600 $28,000
Q4 2022 Feb 14, 2023	SELL	$1.96 - $2.61 $67,620 - $90,045	-34,500 Reduced 61.39%	21,700 $43,000
Q3 2022 Nov 14, 2022	SELL	$2.02 - $3.62 $4,444 - $7,964	-2,200 Reduced 3.77%	56,200 $114,000

186

137M

234K

45.9K

Ticker AMRX
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 151,408,992
Market Cap $1.31B
Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.